康辰药业(603590.SH)：前三季度净利润1.28亿元，同比增长13.19%

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) reported a year-on-year revenue growth of 7.1% for the first three quarters of 2025, reaching a total revenue of 692 million yuan [1] - The net profit attributable to shareholders increased by 13.19% year-on-year, amounting to 128 million yuan [1] - The basic earnings per share stood at 0.81 yuan [1] Financial Performance - Total revenue for the first three quarters: 692 million yuan, representing a 7.1% increase year-on-year [1] - Net profit attributable to shareholders: 128 million yuan, reflecting a year-on-year growth of 13.19% [1] - Basic earnings per share: 0.81 yuan [1]